Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for ...

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.

ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders –– Topline Data Expected Mid-Year 2025 –MELBOURNE, Australia and ...

New research suggests that people who take significantly longer to start the dream phase of sleep may be showing an early ...

"The dosing of our first patient in the Phase 2 clinical trial of YA-101 for Multiple System Atrophy represents a big step forward as we strive to bring a much-needed treatment option to ...

University of Florida researchers have led a multicenter study demonstrating that Automated Imaging Differentiation for ...

Existing research indicates that the accuracy of a Parkinson's disease diagnosis hovers between 55% and 78% in the first five ...

Yoda Therapeutics Inc. (YODA), an AI-driven company that focuses on Central Nervous System (CNS) drugs, today announced the dosing of the first patient in the Phase 2 trial of YA-101 for Multiple ...

The ATH434-202 is an open label study designed to evaluate the safety, efficacy and target engagement of ATH434 in participants with advanced multiple system atrophy (MSA). “Following the ...

Alterity Therapeutics (ATHE) announced that the last patient in the ATH434-202 Phase 2 trial has completed the study. The ATH434-202 is an open ...